Skip to NavigationSkip to content

Dsuvia

Head of opioid advisory panel criticises FDA for complacency in ongoing crisis

The opioid crisis continues to be a top healthcare concern in the US, but the head of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee has called out the drug regulator over its handling of the epidemic.

In an interview with The Guardian, Dr Raeford Brown accused the FDA of complacency in its continued approval of opioid pain medications, in light of a lawsuit against OxyContin manufacturer Purdue Pharma which alleges that the company’s owners, the Sackler family, were personally responsible for directing deceptive sales tactics and peddling deliberate m

FDA controversially approves potent opioid up to ten times stronger than fentanyl

Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five to ten times stronger than fentanyl, for the management of severe, acute pain at a time when the US teeters amidst an addiction epidemic which has claimed the lives of over 71,000 throughout 2017.

The approval decision comes after an advisory committee voted 10-3 in favour of recommending the drug, despite an FDA staff report released prior to the vote questioning its therapeutic benefit compared to other available treatments.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches